Story perspectives

FDA Approves Q-Collar Amid Concerns Over Data Reliability

11/2/2025

27 4

Summary

Story summary

The U.S. Food and Drug Administration (FDA) authorized the Q-Collar as a Class II device via the de novo pathway, indicating moderate risk.
The de novo pathway allows marketing based on reasonable assurance of safety rather than full approval.
Despite claims of a 66% reduction in brain damage risk, internal FDA documents questioned data reliability.
The Q-Collar’s marketing may mislead consumers and highlight calls for greater transparency in FDA approvals.

1 of 1

Story summary

The U.S. Food and Drug Administration (FDA) authorized the Q-Collar as a Class II device via the de novo pathway, indicating moderate risk.
The de novo pathway allows marketing based on reasonable assurance of safety rather than full approval.
Despite claims of a 66% reduction in brain damage risk, internal FDA documents questioned data reliability.
The Q-Collar’s marketing may mislead consumers and highlight calls for greater transparency in FDA approvals.